-
Angiotensin II: From GPCR Signal to Vascular Insight
2026-09-15
A translational framework for using Angiotensin II to connect GPCR signaling with endothelial dysfunction, vascular remodeling, hypertension mechanisms, and abdominal aortic aneurysm models.
-
Azilsartan: A Causal RAS Assay Framework
2026-09-15
Azilsartan (TAK-536) enables receptor-level interrogation of angiotensin II signaling in cardiovascular and neuroinflammation models. This article translates a reactive astrocyte–microglia study into a rigorous assay framework focused on causal interpretation, controls, and reproducibility.
-
Losartan Workflows for AT1R and Kidney Research
2026-09-14
Losartan is a practical angiotensin II receptor antagonist for separating AT1R-dependent signaling from upstream trafficking defects in podocytes, vascular cells, and hypertension models. This guide combines assay-ready preparation, mechanistic readouts, and troubleshooting strategies for reproducible cardiovascular and diabetic kidney research.
-
VX-745: A Practical p38α MAPK Inhibitor Workflow
2026-09-14
VX-745 combines strong biochemical potency for p38α with a practical workflow for cytokine, proliferation, aging, and arthritis studies. This guide translates pathway biology and recent kinase-conformation research into assay setup, protocol choices, and troubleshooting steps.
-
ICAA Targets RIP3 in Cardiac Hypertrophy
2026-09-13
A 2026 Cellular Signalling study identifies isochlorogenic acid A (ICAA) as a protective compound that directly targets RIP3 and suppresses downstream CaMKII signaling in angiotensin II- and pressure overload-induced cardiac hypertrophy. The work separates RIP3-dependent hypertrophic remodeling from canonical MLKL signaling and provides a mechanistic framework for cardiovascular disease research.
-
ICAA Targets RIP3 in Ang II Cardiac Hypertrophy
2026-09-12
The reference study identifies isochlorogenic acid A (ICAA) as a protective compound that acts on RIP3 and suppresses downstream CaMKII signaling during angiotensin II- and pressure overload-induced cardiac hypertrophy. Its key mechanistic contribution is showing that RIP3 regulates hypertrophic remodeling independently of MLKL, providing a rationale for studying the RIP3/CaMKII axis as a distinct therapeutic pathway.
-
Escitalopram B1183 for Reliable Cell Assays
2026-09-12
This scenario-based guide shows how Escitalopram (SKU B1183) can support controlled viability, proliferation, cytotoxicity, and transporter experiments. It connects formulation data, assay design, and translational limitations so researchers can select concentrations, controls, and readouts more defensibly.
-
FITC Goat Anti-Mouse IgG (H+L) Workflow
2026-09-11
Build sensitive immunofluorescence and flow cytometry assays around reliable mouse IgG detection, with practical controls for ovarian-aging research. This workflow combines secondary-antibody signal amplification with troubleshooting strategies for tissue autofluorescence, endogenous mouse immunoglobulin, and FITC photobleaching.
-
Cediranib (AZD2171) In Vitro Workflow
2026-09-11
Cediranib (AZD2171) enables precise interrogation of VEGFR-driven angiogenesis, but its strongest value comes from pairing pathway biomarkers with separate measurements of growth inhibition and cell death. This workflow shows how to build time-resolved assays, distinguish endothelial signaling effects from nonspecific toxicity, and troubleshoot misleading viability results.
-
How Mixing Shapes mRNA LNP Performance
2026-09-10
The reference study isolates primary mixing as a major determinant of mRNA lipid nanoparticle properties and biological performance by comparing ten mixers under otherwise controlled formulation conditions. Its findings explain why manually prepared or laminar-flow particles may not predict the behavior of LNPs produced with turbulent-flow equipment at manufacturing scale.
-
Anti-HMGB1 Rabbit Monoclonal Antibody Guide
2026-09-10
The Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, supports research detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is an unconjugated research reagent for controlled laboratory workflows and should not be used for diagnosis, patient testing, or therapeutic decisions.
-
Afatinib in Gastric Cancer Assembloid Research
2026-09-09
Afatinib (BIBW 2992) provides an irreversible ErbB-family perturbation tool for testing how patient-matched stromal cells reshape drug response in gastric cancer models. This guide translates assembloid findings into practical dosing, assay, controls, and troubleshooting strategies for targeted therapy research.
-
Calcitriol Workflows for VDR Signaling Research
2026-09-09
Calcitriol enables controlled activation of vitamin D receptor signaling in reproductive, immune, and cancer cell models. This practical guide translates recent endometrial decidualization findings into dosing, sampling, assay-selection, and troubleshooting strategies for reproducible bench workflows.
-
ALDH2, Cardiomyocyte Proliferation, and Heart Failure
2026-09-08
A 2025 Experimental Cell Research study identifies ALDH2 as a regulator of cardiomyocyte proliferative competence, not only an enzyme involved in oxidative aldehyde metabolism. In neonatal and pressure-overloaded mouse hearts, ALDH2 activation extended the developmental proliferative window, increased cardiomyocyte proliferation, and delayed heart failure, providing a foundation for regeneration-focused cardiac research.
-
Lambda Protein Phosphatase for BMAL1 Validation
2026-09-08
Use RNase-free Lambda Protein Phosphatase to distinguish phosphorylation-dependent BMAL1 behavior from antibody artifacts and sample-handling effects. This workflow connects phosphatase-sensitive immunoblotting with phase-separation assays, providing practical controls for circadian transcription research.